Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone July 3, 2019 - Canadian Stock Exchange News 0 » View More News for July 03, 2019